Diadema Partners’s Protagonist Therapeutics PTGX Stock Holding History

Diadema Partners’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-22,700	Closed	-$1.98M	–	190
2025 Q4	$1.98M	Sell	22,700 -28,485	-56%	-$2.33M	0.34%	65
2025 Q3	$3.4M	Sell	51,185 -25,000	-33%	-$1.42M	0.87%	40
2025 Q2	$4.21M	Buy	+76,185	New	+$3.66M	1.28%	27

Other funds holding PTGX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Diadema Partners's PTGX Position: Q1 2026 in Review

Diadema Partners sold out of Protagonist Therapeutics (PTGX) in Q1 2026, closing a stake of 22,700 shares — an estimated $1.98M sold.

Diadema Partners first reported a position in PTGX in Q2 2025 and held it in 3 quarters. The position peaked at $4.21M in Q2 2025. 317 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

Diadema Partners reported no remaining Protagonist Therapeutics position as of Q1 2026 after selling out during the quarter.
Diadema Partners sold 22,700 Protagonist Therapeutics shares in Q1 2026, an estimated $1.98M.
Diadema Partners first reported a position in Protagonist Therapeutics in Q2 2025 and held it in 3 quarters.
Diadema Partners's Protagonist Therapeutics position peaked at $4.21M in Q2 2025.
317 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on Diadema Partners's 13F filing for Q1 2026, filed 15 May 2026.